AIM Rule 26 Information

ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, is pleased to confirm that the Company’s Annual General Meeting (“AGM”) will be held on Thursday 25 June 2026 @ 11:00a.m. (BST), at the offices of Broadfield Law UK LLP, One Bartholomew Close, London, EC1A 7BL

The Notice of AGM setting out details of the resolutions, together with the Company’s Annual Report and Accounts for the year ended 31 December 2025, was been posted to those shareholders requesting a postal copy; and for other shareholders, these documents are available to view and download on the Company’s website: www.immupharma.co.uk

Please contact Lisa Baderoon at lisa.baderoon@immupharma.com if you have any questions regarding the AGM.

Advisers

Nominated Adviser ‘NOMAD”
SPARK Advisory Partners Limited
5 St. John’s Lane, London, EC1M 4BH
www.sparkadvisorypartners.com

Joint Broker
Stanford Capital Partners Limited
5-7 Cranwood Street, London, EC1V 9EE
www.stanfordcp.co.uk/contact-us

Joint Broker
Si Capital Limited
46 Bridge St, Godalming, GU7 1HL
info@sicapital.co.uk

Public and Investor Relations
Lisa Baderoon
lisa.baderoon@immupharma.com
investors@immupharma.com

Legal Representatives
Broadfield UK
One Bartholomew Close, London, EC1A 7BL
www.broadfield-law.com

Auditors
Crowe LLP
55 Ludgate Hill, London, EC4M 7JW
www.crowe.com/uk

Patent Agents
Haseltine Lake Kempner LLP
7th Floor, Cheapside House, 138 Cheapside, London, EC2V 6BJ
www.hlk-ip.com

Principal Bankers
Royal Bank of Scotland plc
62/63 Threadneedle Street, London EC2R 8LA
www.rbs.co.uk

Registrars
Computershare Investor Services PLC

The Pavilions, Bridgewater Road, Bristol, BS99 6ZZ
www.computershare.com

Current Constitutional Documents

Please click below for details of current constitutional documents.

Constitutional documents

Proposed Articles of Association

For all notifications, please check the Regulatory News section.

Number of Securities In Issue and Significant Shareholders

ImmuPharma has 623,911,379 ordinary shares of 1p each in issue, each of which entitles the holder to cast one vote in general meetings. The Company does not hold any Ordinary Shares in treasury. As at 10 April 2026, major shareholders, who have provided a TR1 to the Company, are detailed below:

	Number of Ordinary 1p shares	% of issued share capital
Lanstead Capital Investors LP	112,236,910	17.99%
Alora Pharmaceuticals (Avion)	10,909,091	1.75%

The holdings of Directors are as follows:
Tim McCarthy (Chairman & Chief Executive Officer)	1,488,462	0.24%
Dr Tim Franklin (Chief Operating Officer)	525,000	0.08%
Lisa Baderoon (Non-Executive Director and Head of Investor Relations)	1,583,963	0.25%
Dr Sébastien R. Goudreau (Chief Scientific Officer)	150,000	0.02%

As far as the Company is aware, the percentage of ImmuPharma’s issued share capital that is not in public hands is under 1%. This percentage comprises the holdings of Directors only.

ImmuPharma is subject to the UK City Code on Takeovers and Mergers.

Total Warrants and Options Outstanding

Total number of warrants outstanding = 98,042,350

Total number of options outstanding = 45,025,000

For more details click here

Details of any restrictions on the transfer of securities

There are no restrictions on the transfer of securities.

Details of other exchanges or trading platforms

The Company has neither applied for nor agreed to have any of its securities (including its AIM securities) admitted or traded on any other market.

Presentations, circulars, Proxy Forms and Admission Document

Please click here for the link to access the Company’s Notice of the 2026 Annual General Meeting
IMM Notice of the 2026 Annual General Meeting

Please click on the link below to access the Company’s Proxy Form
IMM Proxy Form: Annual General Meeting held on Thursday 25 June 2026

Please click on the link below to access the Company’s circulars
IMM Circular February 2016 Fundrasing

Please click on the link below to access the Company’s Proxy Forms
IMM Proxy Form February 2016 Fundraising

Please click on the link below to access the Company’s Admission Document (January 2006).
ImmuPharma Admission Document

Special rules apply when US persons (as defined in the United States securities laws) access this website. For US regulatory reasons, US residents and other US persons who reside outside the United States are not permitted to access this website. The company is not offering any securities or services in the United States or to residents of the United States through this website or otherwise. Please refer to our Disclaimer.

Last Updated: 10/4/2026